Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nature Medicine2017Vol. 23(2), pp. 256–263
Citations Over TimeTop 10% of 2017 papers
Nikolas Herold, Sean G. Rudd, Linda Ljungblad, Kumar Sanjiv, Ida Hed Myrberg, Cynthia B. J. Paulin, Yaser Heshmati, Anna Hagenkort, Juliane Kutzner, Brent D. G. Page, José Manuel Calderón‐Montaño, Olga Loseva, Ann‐Sofie Jemth, Lorenzo Bulli, Hanna Axelsson, Bianca Tesi, Nicholas C.K. Valerie, Andreas Höglund, Julia Bladh, Elisée Wiita, Mikael Sundin, Michael Uhlin, Georgios Z. Rassidakis, Mats Heyman, Katja Pokrovskaja Tamm, Ulrika Warpman Berglund, Julian Walfridsson, Sören Lehmann, Dan Grandér, Thomas Lundbäck, Per Kogner, Jan‐Inge Henter, Thomas Helleday, Torsten Schaller
Related Papers
- → Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine(2008)20 cited
- → Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia(2023)5 cited
- Dipyrone enhances intracellular accumulation and cytotoxicity of adriamycin in human chronic myeloid leukemia cells.(1991)
- → Interaction between HIV and its host: role for viral and cellular sncRNA(2011)
- → HSA-MIR-12462 INHIBITS THE PROLIFERATION AND RESTORES THE SUSCEPTIBILITY TO CYTARABINE OF ACUTE MYELOID LEUKEMIA (AML) THROUGH INHIBITION OF GLI1(2019)